NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE20690 Query DataSets for GSE20690
Status Public on Mar 09, 2010
Title Efficacy of anti-TNF biologic agent, infliximab, for RA patients using transcriptome analysis of white blood cells
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Introduction of biologics, such as infliximab, to the therapy of rheumatoid arthritis (RA) patients has revolutionized the treatment of this disease. However, biomarkers for predicting the efficacy of the drug at an early phase of treatment for selecting real responders have not been found. We here present predictive markers based on a thorough transcriptome analysis of white blood cells from RA patients. RNA from whole blood cells of consecutive 42 patients before the first infusion was analyzed with microarrays for training studies. Samples from the subsequent 26 consecutive patients were used for a prospective study. We categorized the results into no inflammation and residual inflammation groups using the serum C-reactive protein (CRP) level at 14 weeks after the first infusion. The accuracy of prediction in our study was 65.4%.
 
Overall design Forty-two and 26 consecutive RA patients followed at Saitama Medical Center, for retrospective and verification studies, respectively, who were resistant to standard MTX treatment, were enrolled. The serum CRP level was used for the definition of the level of inflammation of each patient, 0.3 mg/dl or less as “no inflammation” (NI), and more than 0.3 mg/dl as “residual inflammation” (RI) at 14 weeks after the first treatment with infliximab infusion. Differentially expressed genes between the NI and RI patients in the retrospective/training set were extracted, and these genes were verified using the verification set.
 
Contributor(s) Tanino M, Matoba R, Nakamura S, Kameda H, Amano K, Okayama T, Nagasawa H, Suzuki K, Matsubara K, Takeuchi T
Citation(s) 19577537
Submission date Mar 09, 2010
Last update date Feb 22, 2018
Contact name Motohiko Tanino
E-mail(s) tanino@dna-chip.co.jp
Phone +81-45-5211
Fax +81-45-5219
Organization name DNA Chip Research Inc.
Street address 1-1-43, Suehirocho, Tsurumi-ku
City Yokohama
State/province Kanagawa
ZIP/Postal code 230-0045
Country Japan
 
Platforms (1)
GPL4133 Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Feature Number version)
Samples (68)
GSM519451 PAXgeneBlood_PreTreatment_No Inflammation (NI)_Training set_rep1_NI1
GSM519452 PAXgeneBlood_PreTreatment_No Inflammation (NI)_Training set_rep1_NI2
GSM519453 PAXgeneBlood_PreTreatment_No Inflammation (NI)_Training set_rep1_NI3
Relations
BioProject PRJNA125003

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE20690_RAW.tar 525.3 Mb (http)(custom) TAR (of TXT)
Processed data included within Sample table
| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap